Steris PLC (STE)
| Market Cap | 17.14B |
| Revenue (ttm) | 3.06B |
| Net Income (ttm) | 431.87M |
| Shares Out | 85.35M |
| EPS (ttm) | 5.03 |
| PE Ratio | 39.32 |
| Forward PE | 29.85 |
| Dividend | $1.54 |
| Dividend Yield | 0.78% |
| Trading Day | May 12 |
| Last Price | $197.74 |
| Previous Close | $204.65 |
| Change ($) | -6.91 |
| Change (%) | -3.38% |
| Day's Open | 203.34 |
| Day's Range | 197.51 - 203.51 |
| Day's Volume | 536,880 |
| 52-Week Range | 142.79 - 216.74 |
STERIS (STE) is likely to have continued to gain from the robust demand of PPE and COVID-19-related products in Q4.
DUBLIN, IRELAND, May 11, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced changes to its Board of Directors. David Lewis, Board member since 2010 has announced...
DUBLIN, IRELAND, April 27, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2021 fourth quarter and f...
Investors are optimistic about STERIS (STE) backed by elevated consumer demand and strong segmental growth in third-quarter fiscal 2021.
Investors are optimistic about STERIS (STE) owing to strong segmental performance amid the pandemic and huge growth potential in healthcare and pharmaceutical industries.
Steris (STE) reported earnings 30 days ago. What's next for the stock?
NEW ORLEANS, Feb. 9, 2021 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Cantel...
STERIS' (STE) third-quarter fiscal 2021 results reflect strong performance by all three of its reporting segments despite the coronavirus-led economic crisis.
DUBLIN, IRELAND, Feb. 03, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that Walt Rosebrough, President and CEO, has announced his intention to step down o...
Steris (STE) delivered earnings and revenue surprises of 10.90% and 1.68%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Steris (NYSE:STE) moved higher in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 19.31% over the past year to $1.73, which beat the es...
DUBLIN, IRELAND , Feb. 02, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2021 third quarter ended December 31, 2020. Reve...
Steris (NYSE:STE) will be releasing its next round of earnings this Tuesday, February 02. For all of the relevant information, here is your guide for Tuesday's Q3 earnings announcement.
Within Life Sciences, STERIS (STE) might have registered benefits from pharma customers on growing vaccines, along with a recovery in the Healthcare arm in Q3.
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
STERIS to Host a Conference Call for Fiscal 2021 Third Quarter Financial Results on February 3, 2021
DUBLIN, IRELAND, Jan. 19, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2021 third quarter financ...
Steris is a long-term value creator, which combines organic growth with bolt-on acquisitions. The company started 2021 with a big deal, acquiring Cantel in a multi-billion transaction.
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Cantel Medical Cor...
STERIS (STE) expects to strengthen and expand its endoscopy offerings along with extending into a new customer territory via the Cantel Medical buyout.
NEW YORK, Jan. 12, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Cantel Medical Corporation (NYSE: CMD) ("Cantel") and its board of directors concerning th...
Shares of Cantel Medical Corp. rose 1.8% in premarket trading Tuesday, after the infection prevention products company announced an agreement to be acquired by Ireland-based Steris PLC in a cash and equ...
DUBLIN, IRELAND and LITTLE FALLS, N.J, Jan. 12, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) and Cantel Medical Corp (NYSE:CMD) (“Cantel”) today announced that STERIS has ...
DUBLIN, IRELAND, Jan. 07, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that the Company will be publicly webcasting presentations made by Walt Rosebrough, ...
Steris (STE) reported earnings 30 days ago. What's next for the stock?
DUBLIN, IRELAND, Nov. 18, 2020 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that is has completed the previously announced acquisition of Key Surgical, a portfo...
3 Best Buys from the Prospering Medical Instruments Industry
STERIS plc's (STE) CEO Walter Rosebrough on Q2 2021 Results - Earnings Call Transcript
STERIS plc (STE) CEO Walter Rosebrough on Q2 2021 Results - Earnings Call Transcript
STERIS' (STE) second-quarter fiscal 2021 results reflect strong performance by the Life Sciences and the Applied Sterilization Technologies segments despite the coronavirus-led economic crisis.
Steris (STE) delivered earnings and revenue surprises of 19.35% and 7.23%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
DUBLIN, IRELAND , Nov. 02, 2020 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2021 second quarter ended September 30, 2020. Re...
Several medical product stocks have come up with bullish earnings reports so far this reporting cycle. Let's see how STE, HSIC, PACB, INSP are poised ahead of their announcements.
Within Life Sciences, STERIS (STE) might have registered benefit from pharma customers on growing vaccines and biologics businesses in Q2.
COVID-19 has heightened the demand for companies that specialize in infection control.
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DUBLIN, IRELAND, Oct. 20, 2020 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2021 second quarter financ...
Steris (STE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Steris PLC STE, +1.18% said Tuesday it has agreed to acquire Key Surgical, a portfolio company of Water Street Healthcare Partners LLC for $850 million. Dublin, Ireland-based Steris expects the deal to ...
DUBLIN, IRELAND, Oct. 06, 2020 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that the Company has signed a definitive agreement to purchase Key Surgical, a portf...
The U.S. presidential election is less than 50 days away and the health care sector could prove to be the most impacted. On Monday, Chantico Global CEO Gina Sanchez laid out on CNBC’s “Trading Nation” h...
STERIS (STE) is optimistic about maintaining growth momentum on broader product and service portfolio along with strength in its Life Sciences business.
Steris (STE) reported earnings 30 days ago. What's next for the stock?
5 Dividend Increases For The Week Of August 23rd With 1 Dividend King
STERIS plc (STE) CEO Walter Rosebrough on Q1 2021 Results - Earnings Call Transcript
STERIS' (STE) first-quarter fiscal 2021 results reflect strong performance by the Life Sciences segment despite the coronavirus-led economic crisis.
Steris (STE) delivered earnings and revenue surprises of 35.05% and 4.55%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
• First quarter revenue declines low-single digits due to reduction in deferrable procedures • First quarter net income grows low-single digits driven by margin expansion • ...
STERIS (STE) registers declines in Healthcare Products with neutral performance in Life Science and AST in April, which is likely to have impacted Q1 earnings.
DUBLIN, IRELAND, July 22, 2020 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2021 first quarter finan...
About STE
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including... [Read more...]
| Industry Medical Instruments & Supplies | IPO Date Jun 1, 1992 |
| CEO Walter Rosebrough | Employees 13,000 |
| Stock Exchange NYSE | Ticker Symbol STE |
Financial Performance
In 2019, Steris's revenue was $3.03 billion, an increase of 8.94% compared to the previous year's $2.78 billion. Earnings were $407.61 million, an increase of 34.06%.
Analyst Forecasts
According to 7 analysts, the average rating for Steris stock is "Buy." The 12-month stock price forecast is 227.25, which is an increase of 14.92% from the latest price.